List of Excipients in Branded Drug CEFEPIME HYDROCHLORIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	CEFEPIME HYDROCHLORIDE AND DEXTROSE	cefepime hydrochloride	0264-3193	DEXTROSE MONOHYDRATE
B Braun Medical Inc	CEFEPIME HYDROCHLORIDE AND DEXTROSE	cefepime hydrochloride	0264-3193	WATER

Generic Drugs Containing CEFEPIME HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	cefepime hydrochloride	0143-9382	ARGININE
Hikma Pharmaceuticals USA Inc	cefepime hydrochloride	0143-9477	ARGININE
Sandoz Inc	cefepime hydrochloride	0781-3222	ARGININE
Xellia Pharmaceuticals USA LLC	cefepime hydrochloride	70594-089	ARGININE

What are the Most Frequently-Used Excipients in CEFEPIME HYDROCHLORIDE?

# Of NDCs	Excipient
4	ARGININE

Cefepime Hydrochloride Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: October 30, 2026

Cefepime hydrochloride is an established parenteral fourth-generation cephalosporin with limited opportunity for conventional composition-of-matter exclusivity. Commercial value is concentrated in formulation execution: ready-to-administer presentations, improved refrigerated or room-temperature stability, reduced preparation errors, pediatric dosing, compatibility, and differentiated delivery systems.

The principal excipient platform is an arginine-buffered aqueous or lyophilized formulation. Cefepime hydrochloride is highly water soluble but chemically sensitive to pH, temperature, concentration, and container conditions. Formulation development must balance stability against degradation, color formation, reconstitution time, osmolality, and infusion compatibility.

What is cefepime hydrochloride and how is it regulated?

Cefepime hydrochloride is the hydrochloride salt of cefepime, an injectable cephalosporin antibacterial. The FDA approved MAXIPIME, the reference product, in 1996. Current cefepime products are administered intravenously or intramuscularly and are used for serious infections caused by susceptible Gram-negative and Gram-positive bacteria, including pneumonia, febrile neutropenia, urinary tract infections, skin infections, and intra-abdominal infections when combined with metronidazole. Dosing requires adjustment in renal impairment because cefepime is predominantly eliminated by the kidneys. [1]

Cefepime injection products are generally supplied as sterile powder for reconstitution. Commercial products use cefepime hydrochloride, often expressed as cefepime equivalent, with L-arginine as a formulation excipient or buffering component. Dilution may use 0.9% sodium chloride, 5% dextrose, or other labeled compatible solutions, depending on the product. [1-3]

FDA regulatory status

Regulatory element	Cefepime hydrochloride status
FDA route	Abbreviated New Drug Application for generic products
Reference product	MAXIPIME
Dosage form	Sterile injectable powder; some products are supplied as premixed solutions
Administration	Intravenous and intramuscular
Main regulatory issue	Sterility, potency, impurities, reconstitution, compatibility, container closure, and stability
Orange Book relevance	Approved products and therapeutic equivalence listings; generic product patents are not the principal commercial barrier
Biologic status	Not a biologic; biosimilar pathway does not apply
Key safety issue	Neurotoxicity risk, particularly with renal impairment and excessive exposure

What excipients are used in cefepime hydrochloride injections?

The established excipient strategy uses L-arginine to control formulation pH and support cefepime stability. The exact quantity varies by manufacturer, strength, dosage form, and manufacturing process.

Core excipient functions

Excipient or component	Primary function	Commercial significance
L-arginine	Buffering and pH control; may support cefepime stability	Creates a known regulatory platform but can affect osmolality, injection volume, and impurity profile
Water for injection	Solvent for liquid presentations and reconstitution	Controls microbial, particulate, and extractables risk
Dextrose	Diluent in premixed infusion products	Enables ready-to-use products but creates concentration and stability constraints
Sodium chloride	Diluent in premixed infusion products	Supports common hospital workflows; increases sodium load
Nitrogen or inert headspace gas	Oxygen control in selected packaging configurations	May reduce oxidative degradation in liquid products
Container-closure materials	Protection from moisture, oxygen, and light	Important for vial stability, extractables, and shelf life

Cefepime products generally do not require a preservative for single-dose sterile vials. A preservative-containing multidose strategy would introduce additional safety, compatibility, and regulatory burdens and is unlikely to be the preferred route for hospital use.

Why L-arginine matters

L-arginine is more than an inactive filler. It affects pH, ionic strength, osmolality, reconstitution behavior, and the impurity profile. A change in arginine concentration can alter:

• Cefepime degradation rates.
• Solution color after reconstitution.
• Compatibility with infusion materials.
• Injection-site tolerability.
• Maximum feasible drug concentration.
• Lyophilization behavior.
• Regulatory comparability against existing products.

A reformulated product that replaces or materially changes arginine would require a clear stability and clinical-use rationale. The strongest commercial cases involve a measurable operational benefit, such as longer in-use stability, faster preparation, lower administration volume, or simplified storage.

What formulation patents protect cefepime hydrochloride?

The original cefepime product is long off patent in the ordinary commercial sense. Generic cefepime products have competed for many years, and the core cefepime hydrochloride injectable formulation is not protected by a meaningful composition-of-matter monopoly.

Patent opportunities may still exist around narrower technical features:

1. Ready-to-use cefepime solutions.
2. Premixed cefepime infusion bags.
3. Concentrated formulations for reduced infusion volume.
4. Stabilized liquid formulations.
5. Specific pH and buffer systems.
6. Dual-chamber containers.
7. Container-closure systems that reduce moisture or oxygen exposure.
8. Lyophilized cake structures and reconstitution methods.
9. Cefepime combinations with beta-lactamase inhibitors.
10. Manufacturing processes that reduce specified cefepime impurities.

The commercial value of such patents depends on claim scope and design-around difficulty. A patent covering only a narrow arginine concentration or routine vial configuration is weaker than one covering a validated liquid stability platform with defined impurity limits, container requirements, and storage conditions.

Patent strength by claim category

Claim category	Typical strength	Commercial assessment
Cefepime molecule or broad salt claims	Low	Core market is mature and generic
Generic lyophilized cefepime vial	Low	Numerous design-around options
Narrow excipient ratio	Low to moderate	Vulnerable to reformulation and alternative buffers
Stable ready-to-use liquid	Moderate to high	Stronger if stability requires a narrow formulation window
Dual-chamber or closed-system delivery	Moderate	Value depends on device and use claims
Manufacturing impurity-control process	Moderate	Relevant where process performance is difficult to reproduce
Cefepime plus enmetazobactam	High relative to cefepime alone	Separate combination-product estate and clinical value

How should a cefepime excipient strategy be designed?

A commercially viable strategy should begin with the administration setting rather than the active ingredient. Cefepime is already familiar to hospitals, so differentiation must reduce pharmacy labor, preparation risk, storage burden, or total treatment cost.

Strategy 1: Ready-to-use liquid cefepime

A ready-to-use cefepime solution can eliminate vial reconstitution and reduce preparation time. The principal technical challenge is maintaining chemical stability over the proposed shelf life and after removal from controlled storage.

The formulation program should evaluate:

• Cefepime concentration.
• Arginine or alternative buffer system.
• pH range.
• Oxygen exposure.
• Light exposure.
• IV bag and tubing materials.
• Subvisible particles.
• Degradation products.
• Refrigerated and room-temperature storage.
• In-use stability after container entry or spike insertion.

The strongest product profile would combine a single-dose infusion bag with a practical shelf life and minimal pharmacy manipulation. Room-temperature stability would create more value than refrigerated stability because it simplifies ward storage and emergency use.

Strategy 2: Extended-stability premixed bags

Premixed cefepime in dextrose or saline targets hospitals that already use standardized antibiotic infusion protocols. This format can support centralized pharmacy preparation, automated dispensing, and emergency department workflows.

The principal commercial variables are:

• Bag size.
• Drug concentration.
• Infusion duration.
• Refrigerated shelf life.
• Room-temperature excursion allowance.
• Compatibility with elastomeric pumps.
• Availability in common adult and pediatric doses.

A premixed product must not merely match the vial price. Its value proposition should include reduced compounding labor, lower preparation-error risk, reduced waste, and improved antibiotic administration speed.

Strategy 3: Dual-chamber or on-demand reconstitution systems

A dual-chamber device separates cefepime powder from diluent until administration. This approach can address the instability of aqueous cefepime while preserving a ready-to-administer workflow.

Potential advantages include:

• Longer shelf life than a liquid formulation.
• Reduced pharmacy manipulation.
• Lower risk of incorrect diluent selection.
• Suitability for emergency departments, ambulances, and home infusion.
• Simplified use in facilities without centralized sterile compounding.

The principal barriers are device cost, fill-finish complexity, container-closure validation, human-factors testing, and device-related patent exposure.

Strategy 4: Pediatric and renal-dose presentations

Cefepime dosing is clinically sensitive to renal function and patient age. Smaller-dose vials, lower-concentration premixes, or dose-flexible presentations could reduce dose waste and simplify administration.

Opportunities include:

• 250 mg and 500 mg presentations.
• Low-volume pediatric infusion bags.
• Ready-to-use syringes for selected institutional protocols.
• Packaging that supports renal-dose adjustment.
• Barcode-enabled unit doses.

The commercial case is strongest where current vial sizes create high wastage or require repeated aseptic manipulations.

What manufacturing and intellectual-property barriers affect cefepime excipients?

Cefepime hydrochloride is suitable for sterile powder production, but liquid products impose a substantially heavier manufacturing burden. The critical barriers are not the cost of excipients. They are control of degradation, aseptic processing, container compatibility, and validated shelf life.

Manufacturing barriers

Sterile liquid fill-finish

A liquid product requires control of:

• Bioburden before sterilizing filtration.
• Filter adsorption or drug loss.
• Hold-time stability.
• Filling accuracy.
• Particulate generation.
• Container-closure integrity.
• Oxygen exposure during filling.
• Terminal sterilization feasibility.

Cefepime’s chemical stability may make terminal sterilization unsuitable, leaving aseptic processing as the practical route.

Lyophilization

Lyophilized cefepime has a mature manufacturing pathway, but cycle development affects cake appearance, residual moisture, reconstitution time, and impurity formation. L-arginine can alter the freeze-drying behavior and final cake structure. A technically superior cycle may support process patents if it produces a defined impurity profile or improved reconstitution performance.

Packaging

Glass vials are established for cefepime powder. Plastic bags, polymer syringes, elastomeric closures, and dual-chamber systems require extractables and leachables assessment. Oxygen and moisture transmission are central considerations for liquid or low-moisture presentations.

What patent litigation and Paragraph IV risks exist?

Cefepime hydrochloride has a mature generic market, so Paragraph IV litigation risk is generally lower for a conventional vial product than for a newly patented delivery system. The principal litigation risk shifts to:

• New liquid formulations.
• Premixed bags.
• Device-enabled delivery systems.
• Narrow stability claims.
• Combination products with beta-lactamase inhibitors.
• Method-of-use claims linked to resistant infections.

A generic applicant pursuing an ordinary cefepime injection would normally rely on the established reference-product pathway and challenge any listed patents that remain relevant. A formulation developer seeking a premium product must expect potential patent disputes if its product relies on a commercially valuable formulation or device claim.

Combination-product distinction

EXBLIFEP combines cefepime with enmetazobactam, a beta-lactamase inhibitor. The product was approved by the FDA in 2024 for certain complicated urinary tract infections and acute pyelonephritis. Its patent and regulatory position is distinct from cefepime hydrochloride monotherapy. [4]

A company developing a cefepime formulation should avoid assuming that patents covering cefepime-enmetazobactam combinations block cefepime hydrochloride alone. Conversely, an enmetazobactam combination developer must account for combination, formulation, dosing, and method-of-use claims.

How does cefepime compare with competing injectable antibiotics?

Product	Active ingredient	Formulation opportunity	Patent position	Commercial distinction
Cefepime injection	Cefepime hydrochloride	Premix, liquid stability, dual chamber	Mature generic market	Broad hospital familiarity and low acquisition cost
Ceftazidime-avibactam	Ceftazidime plus avibactam	High-value combination formulations	Stronger branded combination estate	Resistant Gram-negative infections
Cefepime-enmetazobactam	Cefepime plus enmetazobactam	Combination stability and delivery	Newer combination-product estate	Expanded activity against selected beta-lactamase producers
Meropenem	Meropenem	Reconstitution and premix systems	Mature but clinically valuable	Broad severe-infection use
Piperacillin-tazobactam	Piperacillin plus tazobactam	Premixed bags and stability	Mature generic market	High-volume hospital use

Cefepime has a lower active-ingredient cost and a larger installed base than newer branded combinations. Its weakness is limited differentiation in the conventional vial market. Its opportunity is operational efficiency.

What licensing deals and partnership models are commercially relevant?

Cefepime excipient opportunities can support several partnership structures:

1. A contract development and manufacturing organization can license a stable liquid platform to a generic sponsor.
2. A hospital-product company can partner with a vial manufacturer to launch premixed bags.
3. A device company can license a dual-chamber or closed-system presentation.
4. A specialty pharmaceutical company can combine cefepime formulation expertise with a beta-lactamase inhibitor.
5. A regional manufacturer can obtain rights for hospital markets where sterile injectable capacity is constrained.

The most defensible licensing package would include formulation claims, analytical methods, stability data, container-closure specifications, and manufacturing know-how. A patent without transferable process knowledge would have limited value because cefepime products are highly sensitive to fill-finish and storage conditions.

What revenue exposure and generic launch scenarios exist?

Conventional cefepime vials are exposed to price competition from multiple generic suppliers. A new entrant would likely face:

• Low reimbursement differentiation.
• Hospital group purchasing pressure.
• Contracting requirements.
• Tender-based pricing.
• Existing generic supply relationships.
• Limited willingness to pay for a minor excipient change.

A premium launch has a stronger probability of commercial adoption when it reduces a measurable hospital cost. The most credible scenarios are:

Base-case scenario

A conventional sterile powder vial enters a mature generic market. Revenue depends on supply reliability, contracting, and manufacturing cost rather than patent exclusivity.

Differentiated scenario

A premixed bag or ready-to-use product earns a premium through lower pharmacy labor and reduced preparation steps. Hospital adoption depends on stability, supply continuity, and reimbursement treatment.

Specialty scenario

A dual-chamber or home-infusion product targets decentralized care. The addressable market is narrower, but the product can command higher value if it reduces compounding requirements.

Combination scenario

Cefepime is paired with a beta-lactamase inhibitor. This creates a new clinical and patent opportunity but requires clinical development, resistance positioning, and a substantially higher regulatory burden.

What geographic markets offer the strongest opportunity?

The United States rewards ready-to-administer hospital products because sterile compounding labor, drug shortages, and pharmacy workflow are material purchasing factors. European markets may favor centralized tendering and standardized presentations. Emerging markets may prioritize vial cost, local manufacturing, and room-temperature storage over advanced delivery systems.

Geographic differentiation should consider:

• Cold-chain reliability.
• Local sterile manufacturing capacity.
• Hospital pharmacy infrastructure.
• Frequency of injectable antibiotic shortages.
• Tender specifications.
• Pediatric demand.
• Home-infusion use.
• Regulatory requirements for premixed products.

A room-temperature-stable liquid or dual-chamber product would have the broadest geographic value because it reduces dependence on refrigeration and local reconstitution infrastructure.

How strong is the cefepime hydrochloride patent estate?

The cefepime hydrochloride monotherapy estate is weak as a blocking platform because the active ingredient and conventional injectable presentation are mature. New value must come from narrow formulation, device, process, or combination claims.

A formulation patent is commercially stronger when it:

• Requires a narrow excipient range.
• Covers a defined stability profile.
• Includes impurity limits linked to the formulation.
• Covers both composition and manufacturing process.
• Applies to a commercially preferred concentration.
• Is difficult to reproduce without the claimed parameters.
• Has enforceable claims across major markets.

A patent limited to routine use of arginine, saline, dextrose, or a standard vial is less likely to prevent design-around. Trade secrets covering fill-finish controls, oxygen management, lyophilization cycles, and analytical release methods may carry greater practical value than a narrow composition claim.

Key Takeaways

• Cefepime hydrochloride is a mature generic injectable with limited conventional patent exclusivity.
• L-arginine is the established excipient platform and affects pH, stability, osmolality, and reconstitution.
• The strongest commercial opportunities are ready-to-use liquids, premixed bags, dual-chamber systems, and pediatric or renal-dose presentations.
• Liquid formulations face higher manufacturing risk than lyophilized vials because of degradation, aseptic processing, oxygen exposure, and container compatibility.
• Conventional cefepime products face substantial price and contracting pressure.
• Formulation patents are more valuable when they combine composition, stability, process, and container claims.
• Cefepime-enmetazobactam is a separate combination-product opportunity with a distinct regulatory and patent estate.
• Biosimilar risk does not apply because cefepime hydrochloride is a small-molecule antibiotic.
• Geographic opportunity is strongest where sterile compounding capacity, refrigeration, or hospital pharmacy labor is constrained.

FAQs

What is the main excipient in cefepime hydrochloride injection?

L-arginine is the principal formulation excipient used in established cefepime hydrochloride injectable products. It supports pH control and formulation stability.

Can cefepime hydrochloride be formulated as a ready-to-use infusion?

Yes. A ready-to-use cefepime infusion is technically possible, but commercial development depends on validated liquid stability, impurity control, container compatibility, sterility assurance, and acceptable storage conditions.

Does cefepime hydrochloride have biosimilar competition?

No. Cefepime hydrochloride is a small-molecule drug and competes through generic-drug pathways rather than the biosimilar pathway.

Are cefepime formulation patents commercially valuable?

They can be valuable when they protect a stable liquid, premixed bag, dual-chamber device, or difficult-to-reproduce manufacturing process. Narrow claims covering routine excipient choices are easier to design around.

Is cefepime-enmetazobactam the same product as cefepime hydrochloride?

No. Cefepime-enmetazobactam is a combination product containing cefepime and the beta-lactamase inhibitor enmetazobactam. Its clinical, regulatory, and patent position is separate from cefepime hydrochloride monotherapy.

References

1. U.S. Food and Drug Administration. (1996). MAXIPIME (cefepime hydrochloride) prescribing information. FDA.

2. DailyMed. (n.d.). Cefepime hydrochloride injection prescribing information. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). EXBLIFEP (cefepime and enmetazobactam) prescribing information. FDA.